Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179326
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Albshesh, Ahmad | - |
dc.contributor.author | Taylor, Joshua | - |
dc.contributor.author | Savarino, Edoardo V. | - |
dc.contributor.author | Truyens, Marie | - |
dc.contributor.author | Armuzzi, Alessandro | - |
dc.contributor.author | Ribaldone, Davide G. | - |
dc.contributor.author | Shitrit, Ariella Bar-Gil | - |
dc.contributor.author | Fibelman, Morine | - |
dc.contributor.author | Molander, Pauliina | - |
dc.contributor.author | Liefferinckx, Claire | - |
dc.contributor.author | Nancey, Stephane | - |
dc.contributor.author | Korani, Mohamed | - |
dc.contributor.author | Rutka, Mariann | - |
dc.contributor.author | Barreiro de Acosta, Manuel | - |
dc.contributor.author | Domislovic, Viktor | - |
dc.contributor.author | Suris, Gerard | - |
dc.contributor.author | Eriksson, Carl | - |
dc.contributor.author | Alves, Catarina | - |
dc.contributor.author | Mpitouli, Afroditi | - |
dc.contributor.author | Di Jiang, Caroline | - |
dc.contributor.author | Tepeš, Katja | - |
dc.contributor.author | Coletta, Marina | - |
dc.contributor.author | Foteinogiannopoulou, Kalliopi | - |
dc.contributor.author | Gisbert, Javier P. | - |
dc.contributor.author | Amir-Barak, Hadar | - |
dc.contributor.author | Attauabi, Mohamed | - |
dc.contributor.author | Seidelin, Jakob | - |
dc.contributor.author | Afif, Waqqas | - |
dc.contributor.author | Marinelli, Carla | - |
dc.contributor.author | Lobatón, Triana | - |
dc.contributor.author | Pugliese, Daniela | - |
dc.contributor.author | Maharshak, Nitsan | - |
dc.contributor.author | Cremer, Anneline | - |
dc.contributor.author | Limdi, Jimmy K. | - |
dc.contributor.author | Molnár, Tamás | - |
dc.contributor.author | Otero Alvarin, Borja | - |
dc.contributor.author | Krznaric, Zeljko | - |
dc.contributor.author | Magro, Fernando | - |
dc.contributor.author | Karmiris, Konstantinos | - |
dc.contributor.author | Raine, Tim | - |
dc.contributor.author | Drobne, David | - |
dc.contributor.author | Koutroubakis, Ioannis | - |
dc.contributor.author | Chaparro, Maria | - |
dc.contributor.author | Yanai, Henit | - |
dc.contributor.author | Burisch, Johan | - |
dc.contributor.author | Kopylov, Uri | - |
dc.date.accessioned | 2021-07-22T11:08:34Z | - |
dc.date.available | 2021-07-22T11:08:34Z | - |
dc.date.issued | 2021-06-29 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/179326 | - |
dc.description.abstract | Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm10132914 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2021, vol. 10, num. 13, p. 2914 | - |
dc.relation.uri | https://doi.org/10.3390/jcm10132914 | - |
dc.rights | cc by (c) Albshesh, Ahmad et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malaltia de Crohn | - |
dc.subject.classification | Malalties inflamatòries intestinals | - |
dc.subject.other | Inflammatory bowel diseases | - |
dc.subject.other | Crohn's disease | - |
dc.title | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-07-22T10:37:58Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34209880 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-10-02914-v3.pdf | 1.16 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License